Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Freywald

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Molecular Oncology|December 15, 2018
Molecular characterization of an MLL1 fusion and its role in chromosomal instabilitySreejit Parameswaran, Frederick S Vizeacoumar, Kalpana Kalyanasundaram Bhanumathy, et al.
Gynecologic Oncology|October 11, 2023
Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomasMartin Köbel, Rui Zhe Yang, Eun Young Kang, et al.
Molecular and Cellular Biology|May 13, 2015
Spindle Checkpoint Factors Bub1 and Bub2 Promote DNA Double-Strand Break Repair by Nonhomologous End JoiningMatthew Jessulat, Ramy H Malty, Diem-Hang Nguyen-Tran, et al.
Oncogene|April 29, 2025
A novel role for Neurog2 in MYCN driven neuroendocrine plasticity of prostate cancerPrachi Walke, Jared D W Price, Frederick S Vizeacoumar, et al.
Gynecologic Oncology|July 6, 2024
Preclinical 3D model screening reveals digoxin as an effective therapy for a rare and aggressive type of endometrial cancerPooja Praveen Kumar, DuPreez Smith, James Key, et al.
Oncogene|April 28, 2018
EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumoursBehzad M Toosi, Amr El Zawily, Luke Truitt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2023
A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2-Bispecific Antibody for Combination Cancer TherapyAmr El Zawily, Frederick S Vizeacoumar, Renuka Dahiya, et al.
Oncotarget|August 25, 2016
Therapeutic relevance of the protein phosphatase 2A in cancerChelsea E Cunningham, Shuangshuang Li, Frederick S Vizeacoumar, et al.
Signal Transduction and Targeted Therapy|June 3, 2026
Epigenetic control of telomeric RNA maintains heterochromatin in telomerase-driven cancersJared D W Price, Frederick S Vizeacoumar, Omar Abuhussein, et al.
Cell Genomics|May 10, 2025
Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethalityChelsea E Cunningham, Frederick S Vizeacoumar, Yue Zhang, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Molecular Oncology|December 15, 2018
Molecular characterization of an MLL1 fusion and its role in chromosomal instabilitySreejit Parameswaran, Frederick S Vizeacoumar, Kalpana Kalyanasundaram Bhanumathy, et al.
Gynecologic Oncology|October 11, 2023
Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomasMartin Köbel, Rui Zhe Yang, Eun Young Kang, et al.
Molecular and Cellular Biology|May 13, 2015
Spindle Checkpoint Factors Bub1 and Bub2 Promote DNA Double-Strand Break Repair by Nonhomologous End JoiningMatthew Jessulat, Ramy H Malty, Diem-Hang Nguyen-Tran, et al.
Oncogene|April 29, 2025
A novel role for Neurog2 in MYCN driven neuroendocrine plasticity of prostate cancerPrachi Walke, Jared D W Price, Frederick S Vizeacoumar, et al.
Gynecologic Oncology|July 6, 2024
Preclinical 3D model screening reveals digoxin as an effective therapy for a rare and aggressive type of endometrial cancerPooja Praveen Kumar, DuPreez Smith, James Key, et al.
Oncogene|April 28, 2018
EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumoursBehzad M Toosi, Amr El Zawily, Luke Truitt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2023
A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2-Bispecific Antibody for Combination Cancer TherapyAmr El Zawily, Frederick S Vizeacoumar, Renuka Dahiya, et al.
Oncotarget|August 25, 2016
Therapeutic relevance of the protein phosphatase 2A in cancerChelsea E Cunningham, Shuangshuang Li, Frederick S Vizeacoumar, et al.
Signal Transduction and Targeted Therapy|June 3, 2026
Epigenetic control of telomeric RNA maintains heterochromatin in telomerase-driven cancersJared D W Price, Frederick S Vizeacoumar, Omar Abuhussein, et al.
Cell Genomics|May 10, 2025
Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethalityChelsea E Cunningham, Frederick S Vizeacoumar, Yue Zhang, et al.
Pageof 7